Actively Recruiting

Phase 4
Age: 18Years +
All Genders
NCT06162377

Methylnatrexone In Resectable Head and Neck Squamous Cell Carcinoma (MINK). A "Window of Opportunity" Pilot Study.

Led by M.D. Anderson Cancer Center · Updated on 2025-12-17

25

Participants Needed

1

Research Sites

155 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

To learn if OCSCC patients can be safely given methylnaltrexone for 2 weeks before surgery.

CONDITIONS

Official Title

Methylnatrexone In Resectable Head and Neck Squamous Cell Carcinoma (MINK). A "Window of Opportunity" Pilot Study.

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • 18 years of age or older
  • Histologically-confirmed oral cavity squamous cell carcinoma (T1-T4, N any) amenable to curative-intent surgery
  • Able to receive the study drug for at least two weeks before surgery
  • Willing and able to comply with scheduled visits, treatment plans, lab tests, and other study procedures
  • Women of child-bearing potential and men must agree to use adequate contraception during the study unless exempt due to postmenopausal status, surgical sterilization, or ovarian failure
  • Ability to understand and sign written informed consent
Not Eligible

You will not qualify if you...

  • Receiving any other investigational agents
  • Non-English or non-Spanish speaking
  • History of allergic reactions to methylnaltrexone or similar compounds
  • Uncontrolled illness including chronic kidney disease (eGFR <60 ml/min) or liver disease with elevated enzymes or bilirubin
  • Psychiatric illness or social situations limiting study compliance
  • Urgent or emergency surgery
  • Known distant metastatic disease
  • Primary brain tumors or brain metastases
  • Pregnant or breastfeeding women
  • Peptic ulcer, intestinal perforation, colitis, Crohn's disease, diverticulitis, Ogilvie's syndrome, intestinal obstruction, or severe diarrhea
  • Use of other opioid antagonists

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

MD Anderson Cancer Center

Houston, Texas, United States, 77030

Actively Recruiting

Loading map...

Research Team

J

Juan Cata, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Methylnatrexone In Resectable Head and Neck Squamous Cell Carcinoma (MINK). A "Window of Opportunity" Pilot Study. | DecenTrialz